Citius Oncology (CTOR) Operating Expenses (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Operating Expenses data on file, last reported at $30.0 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 300.89% year-over-year to $30.0 million in Q1 2026; TTM through Mar 2026 was $48.0 million, a 72.9% increase from a year earlier, with the FY2025 full-year figure at $23.5 million, up 14.34% from the prior year.
• Operating Expenses for Q1 2026 stood at $30.0 million, up from $8.4 million in the prior quarter.
• Over the last five years, Operating Expenses for CTOR reached as high as $30.0 million in Q1 2026 and fell as low as $177922.0 in Q1 2023.
• Historically, Operating Expenses has averaged $7.6 million across 4 years, with a median of $5.7 million in 2024.
• Across the five-year window, Operating Expenses surged 5956.88% in 2024 and tumbled 64.43% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $4.6 million in 2023, then jumped by 39.52% to $6.4 million in 2024, then surged by 31.47% to $8.4 million in 2025, then soared by 256.27% to $30.0 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $30.0 million in Q1 2026, $8.4 million in Q4 2025, and $4.7 million in Q3 2025.